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Composition of healthy microbiota can be compromised by
certain factors leading to dysbiosis, gut barrier dysfunction,
and liver disease. A more detailed picture of the intestinal
microbiota contributing to liver disease beyond increasing
intestinal permeability has started to evolve.
The leaky gut hypothesis links translocating microbial
products with the onset and progression of liver disease,
and for a long time they were considered one of its major
contributors. However, a more detailed picture of the in-
testinal microbiota contributing to liver disease started to
evolve. The gut is colonized by trillions of microbes that aid
in digestion, modulate immune response, and generate a
variety of products that result from microbial metabolic
activities. These products together with host-bacteria in-
teractions inﬂuence both normal physiology and disease
susceptibility. A disruption of the symbiosis between
microbiota and host is known as dysbiosis and can have
profound effects on health. Qualitative changes such as
increased proportions of harmful bacteria and reduced
levels of beneﬁcial bacteria, and also quantitative changes
in the total amount of bacteria (overgrowth) have been
associated with liver disease. Understanding the link be-
tween the pathophysiology of liver diseases and composi-
tional and functional changes of the microbiota will help in
the design of innovative therapies. In this review, we focus
on factors resulting in dysbiosis, and discuss how dysbiosis
can disrupt intestinal homeostasis and contribute to liver
disease. (Cell Mol Gastroenterol Hepatol 2015;1:275–284;
http://dx.doi.org/10.1016/j.jcmgh.2015.04.003)
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The microbiota has a collective genome (microbiome) that
has 150-fold more genes than the human genome as
determined with high-throughput DNA sequencing.1 Bacte-
ria provide a variety of beneﬁcial products that result from
metabolic activities. These products are essential nutrients
and maximize the efﬁciency of energy harvest from ingested
food and together with host-bacteria interactions inﬂuence
both normal physiology and disease susceptibilities.2–4 Gut
microbiota homeostasis is tightly regulated by environ-
mental and genetic factors and a specialized mucosalimmune system. Host immunity and microbiota are
dependent on each other.4,5 Disruption of the microbial
homeostasis is associated with obesity,6 malnutrition,7 in-
ﬂammatory bowel diseases (IBD),8 neurologic disorders,9
cancer,10 and liver diseases,11–16 among others.
Here we describe recent advances in understanding gut
microbiota composition and review how disruption of mi-
crobial and intestinal homeostasis contributes to the most
prevalent chronic liver diseases: nonalcoholic fatty liver
disease (NAFLD) and steatohepatitis (NASH), which are
both commonly associated with obesity, and alcoholic liver
disease. We will also discuss cirrhosis as end-stage liver
disease.
Factors Contributing to Intestinal
Dysbiosis
Environmental Factors That Shape
the Microbiota in Liver Disease
Differences in intestinal microbial composition in dizy-
gotic as well as monozygotic twins suggest that the environ-
ment is in fact an important factor shaping themicrobiome.17
Obesity is associated with phylum-level changes in the
microbiota, less bacterial diversity, and different expression
of bacterial genes and metabolic pathways. For instance, the
microbial inhabitants from populations with similar cultural
factors such as hygiene, exposure to chemicals and/or anti-
biotics, and especially diet share more similarities in the
microbiome structure when compared with populations in
other countries.3 Diet is therefore an important environ-
mental factor.
Bacteria extract energy from the diet. The observed as-
sociations between gut microbes and nutrient absorption
indicate that human gut microbiota regulates nutrient har-
vest. A 20% increase in Firmicutes and a corresponding
decrease in Bacteroidetes were associated with an increased
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extracting energy from various dietary ingredients favors
the growth and/or colonization of certain bacterial strains,
thereby contributing to this complex and competitive envi-
ronment.18 Conventionally raised mice have a 40% higher
body fat content and 47% higher epididymal fat content
than germ-free mice even though they consumed less food
than their germ-free counterparts. Fecal transplantation to
gnotobiotic mice resulted in a 60% increase in body fat
within 2 weeks without any increase in food consumption
or obvious differences in energy expenditure.19
Alcohol consumption is another environmental factor
affecting the composition of the intestinal microbiome.
Alcohol causes intestinal bacterial overgrowth in
humans20,21 and in animal models of chronic alcohol
administration.12,14 Alcohol also results in alcohol-associated
qualitative changes of the microbiota in humans20–22 and
experimental animal models.12,14,23–25 In particular, beneﬁ-
cial commensal bacteria including Lactobacillus are relatively
lower after chronic alcohol consumption.12,20 Using meta-
genomics andmetabolomics, we have recently demonstrated
that chronic alcohol administration results in a decreased
capacity of the intestinal microbiome to produce long-chain
fatty acids (LCFA) in both alcoholics and mouse models of
alcoholic liver disease. This leads to reduced intestinal levels
of saturated LCFA and commensal lactobacilli, which are able
to use saturated LCFA as an energy source.25 A decrease in
beneﬁcial commensal bacteria contributes to a tight junction
barrier disruption.26 Supplementing saturated LCFA main-
tains eubiosis, stabilizes the intestinal gut barrier, and re-
duces ethanol-induced liver disease in mice. Ethanol exerts a
direct effect on the saturated fatty acid biosynthetic gene
abundance in intestinal bacteria independently of the host.25
Antibiotics are important drugs to treat infectious dis-
eases and other diseases that depend on translocated mi-
crobial products. However, antibiotics also can promote
dysbiosis, which might not only favor colonization27 but also
affect body physiology by inducing weight gain. Subthera-
peutic administration alters the population structure of the
gut microbiome and its metabolic capabilities, and increases
adiposity in young mice.28 Thus, dysbiosis induced by an-
tibiotics is an important pathogenic factor in the onset or
progression of systemic diseases. This concept has been
shown in IBD.29–31 Other environmental factors that shape
microbiota are delivery mode,32 smoking,33–35 and parasitic
infections.36Genetic Factors Leading to Intestinal Dysbiosis
The microbiota from family members has more similar-
ities than that from unrelated individuals,37,38 which raises
the possibility that genetic factors affect the microbiome
composition. This is supported by genetic loci in mice that
have been linked to the abundance of gut bacteria.39 It is
important to consider that studies that have failed to ﬁnd
signiﬁcant genotype effects onmicrobiome diversity3,17 were
not accounting for environmental conditions and might have
been underpowered. Newer, sufﬁciently powered studies
have demonstrated that the Christensenellaceae family is aheritable taxon which forms a co-occurrence network with
other heritable taxa and is enriched in individuals with a low
body mass index (BMI).40 Adding Christensenellaceae to an
obese-associated microbiome resulted in reduced weight
gain in the recipient mice.40 Similarly, there is a signiﬁcant
association between the nucleotide-binding oligomerization
domain 2 (NOD2) risk allele for intestinal bowel disease and
an increased relative abundance of Enterobacteriaceae.41
Concerning liver disease, NOD2 variants increase the risk
for culture-positive spontaneous bacterial peritonitis and
bacterascites in cirrhosis and may affect survival.42,43 Ge-
netic polymorphisms of NOD2 are associated with increased
mortality in nonalcoholic liver transplant patients.44
Inﬂammasomes recognize pathogen-associated molecular
patterns (PAMPs) or damage-associated molecular patterns
(DAMPs) that cleavage proinﬂammatory cytokines such as
pro-interleukin (IL)-1b44 and pro-IL-18. Mice deﬁcient for
nucleotide-binding domain and leucine-rich repeat-con-
taining protein 6 (NLRP-6), and hence less intestinal IL-18,
showed altered fecal microbiota characterized by an in-
crease of the bacterial phyla Bacteroidetes (Prevotellaceae)
and TM7.45 Intestinal dysbiosis causes inﬂammation of the
colon, which is mediated by chemokine (C-C motif) ligand 5
(CCL5).46 Intestinal inﬂammation results in an increase in
intestinal permeability, which leads to translocation of mi-
crobial products to the liver. Binding of these microbial
products to Toll-like receptors (TLRs) in the liver is asso-
ciated with exacerbated hepatic steatosis driving NASH
progression. Furthermore, cohousing of inﬂammasome-
deﬁcient mice with wild-type mice results in exacerbation
of hepatic steatosis. NLRP3 and NLRP6 inﬂammasomes and
the effector IL-18 ameliorate NAFLD/NASH progression,
thus highlighting the importance of genetic factors for in-
testinal dysbiosis and systemic diseases.46 The fact that
healthy siblings of patients with Crohn’s disease manifest
Crohn’s disease associated immune and microbiologic fea-
tures supports the relevance of genetic factors in the
composition of microbiota.47
Separating the inﬂuence of genetics and environment on
microbiota composition requires carefully designed studies
to identify a microbiota that is associated with liver disease.
Variables such as antibiotics usage, diet preferences, and
environmental exposures need to be controlled for when the
inﬂuence of a genetic or environmental factor is evaluated.
Whether known genetic risk alleles for liver disease affect
the microbiome composition or the mucosal immune system
deserves future studies.Mucosal Immune System
The immune system is very important in maintaining the
symbiotic relationship between the host and the intestinal
microbiome. Intestinal bacteria develop and regulate the
host immune system,48 and the immune system affects the
composition of the intestinal microbiome. In particular, the
mucosal immune system ensures a beneﬁcial microbiota
composition by restricting the growth of pathogens, con-
trolling bacterial overgrowth, and reacting to pathogens and
bacteria that reach the intestinal barriers, chemical barriers
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physical barriers (the mucus layer and the tightly inter-
connected intestinal epithelial lining).49–51
Host IgA response is primarily directed toward speciﬁc
bacteria within the mucosa, and this bias is disrupted in
animals deﬁcient for MyD88 in T cells (T-MyD88/).
T-MyD88/ animals showed increased dissimilarity in
both their IgA-bound and mucosa-associated communities
and increased total bacterial load at the mucosa. Thus,
innate signaling by T cells dictates IgA speciﬁcity to
constrain the composition of the microbial community,
while also limiting mucosal association of commensal mi-
crobes.52 MyD88 signaling in T cells directs IgA-mediated
control of the microbiota to promote health. In addition,
gut microbiota-derived ﬂagellin is recognized by dendritic
cells in lamina propria via TLR-5, inducing the differentia-
tion of B cells into IgA-producing plasma cells.5 IgA-deﬁcient
mice produce gut microbiota-speciﬁc serum IgG antibodies
due to mucosal barrier disruption and activation of the
systemic immune system.53 Furthermore, the host protein
programmed cell death 1 (PD1) partially regulates the mi-
crobial modulation of IgA homeostasis; PD1-deﬁcient mice
had an altered IgA repertoire and changes in microbial
communities of the gut.54 The importance of IgA for
microbiota composition and mucosal defense remains to be
studied in chronic liver diseases.
The gut microbiota also regulates the production of AMP
such as defensins, C-type lectins (eg, regenerating islet-
derived 3b [Reg3b] and Reg3g), ribonucleases (eg, angio-
poietin 4), and S100 proteins (eg, psoriasin) in intestinal
epithelial cells and Paneth cells, which rapidly kill or inac-
tivate microorganisms.51 Altered AMP production is evident
in mice deﬁcient for MYD88, NOD2, or metalloproteinase-7
(MMP7), a protease involved in the regulation of defensin
activity, as well as in mice that are transgenic for a-defensin
5.55–57 We have shown that chronic alcohol administration
results in suppression of intestinal Reg3b and Reg3g
expression in mice.12,14 The Reg3g level can be restored
using prebiotics, which are associated with suppression of
intestinal bacterial overgrowth.14 Patients who abuse
alcohol similarly have decreased Reg3g expression in the
duodenum.14 Cirrhotic rats with ascites and translocation of
viable bacteria to mesenteric lymph nodes produce lower
levels of defensins and Reg3 molecules compared with
cirrhotic rats without bacterial translocation. This reduction
is accompanied by reduced antimicrobial activity against
Enterobacteriaceae.58 Further studies are required to
determine whether and to what extent lower levels of AMP
contribute to liver disease progression by either modulating
the composition of the intestinal microbiota or facilitating
bacterial translocation.
Furthermore, goblet cells are secreting mucins, which
are highly glycosylated and responsible for the formation of
the inner and outer mucus layer. Mucin-2 is the major
secreted mucin in the small and large intestines of mice and
humans.59 The mucus layer with its expression of certain
lectins shapes the bacterial composition. Bacteria express
glycosidases and metabolic enzymes, which allows them to
bind to or even use the mucus layer as a source ofenergy.60,61 Although the absence of mucin-2 in mice in-
creases the susceptibility to enteric infections,62 the innate
immune system is on high alert and activated to maintain
intestinal homeostasis.63 In fact, mucin-2–deﬁcient mice
showed much higher expression of antimicrobial proteins
and were protected from intestinal bacterial overgrowth
and dysbiosis in response to alcohol feeding. Subsequently,
lower amounts of bacterial products such as endotoxin
translocated into the systemic circulation, thereby
decreasing ALD.12 This is an example of the interconnection
between the different intestinal defense layers and the
microbiota.
Interestingly, in patients with liver cirrhosis most taxo-
nomically assigned species are of buccal origin, suggesting
an invasion of bacteria from the mouth to the intestine.64
Liver cirrhosis is known to be accompanied by decreased
innate immune system surveillance, including lower gastric
acid secretion,65 reduced bile ﬂow,66 and impaired AMP
production.58 Compromised host defense might contribute
to the migration of the oral to the intestinal microbiome.
However, to which degree each individual factor contributes
to compositional changes in the microbiota requires further
analysis.Intestinal Dysbiosis Associated With
Liver Disease
We have summarized the bacterial taxonomic changes in
ALD, NAFLD/NASH, and cirrhosis in recent reviews.67,68
Interestingly, most of the precirrhotic liver diseases and
cirrhosis are associated with intestinal bacterial overgrowth
(described in detail in our aforementioned reviews). No
single bacterial species has been mechanistically linked to
the onset or progression of liver disease. Dietary habits may
induce dysbiosis, characterized by an increased percentage
of intestinal Gram-negative bacteria. Indeed, Gram-negative
proteobacteria are a transplantable phylum that accelerates
cholestatic liver ﬁbrosis.69 As shown by us and described in
more detail previously, the reversal of metabolic intestinal
changes improves ALD.25 Future studies should establish
causative correlations between functional rather than
taxonomic microbiota changes and the pathogenesis of liver
disease.
Leaky Gut Hypothesis—Truth or Myth?
Many of the precirrhotic liver diseases are associated
with increased intestinal permeability. For example, a high-
fat diet (HFD) increases intestinal permeability in mice70
and humans.71 Patients with NAFLD have signiﬁcantly
increased intestinal permeability and more disrupted tight
junctions than healthy individuals.72 Chronic alcohol abuse
results in a disruption of the intestinal barrier.73
How is the gut barrier being disrupted, and is this
dependent on the microbiome and dysbiosis? Although
there is a possibility that liver disease itself increases in-
testinal permeability, intestinal inﬂammation might directly
cause a gut barrier dysfunction and the translocation of
microbial products. Intestinal inﬂammation is commonly
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mucosa inﬂammation is characteristic in obesity.74 HFD
increases the activity of the transcription factor nuclear
factor-kB (NFkB) and expression of tumor necrosis factor-a
(TNFa) in the small intestine of mice. HFD-induced intesti-
nal inﬂammation depends on the enteric microbiota,
because germ-free mice are protected from inﬂammatory
changes.75 As discussed earlier, NLRP3 and NLRP6 deﬁ-
ciency promotes intestinal dysbiosis, triggers colonic
inﬂammation via chemokine (C-C motif) ligand 5 (CCL5),
and increases intestinal permeability. Microbial products
translocate to the liver, enhance hepatic inﬂammation, and
cause NAFLD to progress to steatohepatitis.46 As a marker
of a disrupted mucosal barrier, the systemic levels of LPS
are elevated in HFD-fed mice70 and humans after a high-fat
meal.76,77 Endotoxemia is observed in children with
NAFLD78 and in patients with NASH.79
Similarly, chronic alcohol feeding results in subclinical
intestinal inﬂammation in mice. The number of TNFa-pro-
ducing monocytes and macrophages in the small intestine
increases in mice chronically administered alcohol. These
ﬁndings were conﬁrmed in duodenal biopsy samples from
patients with chronic alcohol abuse. Intestinal decontami-
nation with nonabsorbable antibiotics reduced intestinal
bacterial overgrowth, decreased intestinal inﬂammation and
permeability, and reduced ALD in mice. These ﬁndings
suggest that dysbiosis causes intestinal inﬂammation and
gut barrier dysfunction, although the triggering microbial
metabolite or product is currently not known.
In tissue-speciﬁc genetically manipulated mice, the TNF-
receptor-1 (TNFR-1) expressed on intestinal epithelial cells
was identiﬁed as a target for TNFa secreted from inﬂam-
matory cells in the lamina propria. Our results suggest that
dysbiosis-induced intestinal inﬂammation and TNFR-1
signaling on enterocytes are mediating a disruption of the
intestinal barrier and most importantly ALD. Therefore, in-
testinal TNFR-1 is a crucial mediator of ALD.16
Both, experimental cirrhosis and human cirrhotics, show
features of intestinal inﬂammation.80–82 Whether intestinal
inﬂammation associated with cirrhosis depends on the gut
microbiome is not known. Microbial products or PAMPs
translocate through disrupted tight junctions using the
paracellular route from the intestinal lumen to extra-
intestinal tissues and organs, but living bacteria appear to
translocate via the transcellular route (transcytosis).83
During decompensated cirrhosis, a further increase in in-
testinal permeability could be triggered by intestinal
inﬂammation and may contribute to enhanced translocation
of viable bacteria.84
PAMPs reach the liver via the portal system and activate
speciﬁc pattern recognition receptors including TLRs. TLR
signaling promotes liver inﬂammation and damage.67 Mice
that express nonfunctional molecules in the TLR signaling
pathway are often protected from liver disease.85–88
Signaling via the LPS receptor TLR4 in hematopoietic-
derived cells is required for the development of liver stea-
tosis but not for the development of obesity in mice.89 Mice
deﬁcient in sensing PAMPs or downstream signaling are
resistant to NASH.90,91Bacterial overgrowth correlates with an increase in the
luminal amount of PAMPs. Thus, in the presence of an in-
testinal barrier dysfunction, the luminal bacterial load de-
termines the amount of PAMPs that translocate to the
systemic circulation and hence the degree of liver damage.12
Antibiotics seem to have a beneﬁcial effect by reducing the
intestinal bacterial burden, which in turn reduces the
amount of translocating PAMPs. Intestinal decontamination
improves several diseases that are dependent on increased
intestinal permeability and elevated systemic levels of
PAMPs. Treatment of obese mice with antibiotics improves
glucose metabolism and reduces adiposity and adipose
inﬂammation.92 Intestinal decontamination improves
experimental ALD as a preventive strategy93 and as an
intervention.16 Nonabsorbable antibiotics have a beneﬁcial
effect on toxic and cholestatic liver ﬁbrosis87 and NASH.94 A
clinical trial in patients with ALD using the nonabsorbable
antibiotic paromomycin did not show an improvement in
liver damage compared with placebo-treated patients.95
Because systemic endotoxemia was not reduced after 4
weeks of treatment, antibiotic therapy might not have been
effective, or it might have induced dysbiosis. Cirrhotics
suffering from hepatic encephalopathy are commonly
treated with nonabsorbable antibiotics, which decreases the
number of ammonia-producing intestinal bacteria and im-
proves the mental status of patients with end-stage liver
disease.96 In addition, antibiotics reduce the translocation of
viable bacteria from the intestinal lumen to extraintestinal
space such as mesenteric lymph nodes in experimental
cirrhosis.94
All the above evidence strongly argues for an important
role of microbial products that translocate from the intes-
tine to the liver. Interestingly, not all patients with alcohol
dependence show increased intestinal permeability. Alco-
holics could be divided into low and high gut permeability
groups, with the low permeability group having a similar
permeability as healthy controls. Alcoholics with high in-
testinal permeability also had an altered composition and
activity of the gut microbiota such as lower amounts of
Biﬁdobacterium spp., Clostridiales Family XIV incertae sedis,
and Ruminococcaceae when compared with healthy con-
trols. Levels of these bacteria were not changed in alcoholics
with a low intestinal permeability. Importantly, higher in-
testinal permeability was associated with higher scores of
depression, anxiety, and alcohol craving after 3 weeks of
abstinence.20 Whether liver disease correlates with the de-
gree of intestinal permeability in humans requires further
study.
To conﬁrm the importance of the intestinal microbiota
for chronic liver disease, we induced liver ﬁbrosis in
germ-free and conventional mice by administration of thi-
oacetamide via the drinking water. To our surprise, germ-
free mice showed more liver ﬁbrosis than conventional
mice. To conﬁrm our results we used a second model of
liver ﬁbrosis by repeated intraperitoneal injections of car-
bon tetrachloride, switched the source of germ-free mice,
and used a different gnotobiotic facility, but we still found
exacerbated liver ﬁbrosis in the absence of the microbiota.
Using an additional genetic model with mice lacking
May 2015 Gut Microbiota and Liver Disease 279Myd88/Trif and hence downstream innate immunity
signaling, we identiﬁed hepatocytes to be more susceptible
to toxin-induced cell death.97 Thus, although microbial
products are related to inﬂammation and progressive liver
disease, the complete absence of PAMPs also has a dele-
terious effect on the liver. It is feasible that metabolic
products from the microbiota might provide hep-
atoprotection and might ameliorate chronic liver diseases.For example, indole-3 propionic acid is a deamination
product of dietary tryptophan, and its production is
completely dependent on the presence of the gut micro-
biota.98 Indole-3 propionic acid was recently shown to
protect the intestinal barrier through the xenobiotic sensor
pregnane X receptor (PXR).99 Meta-transcriptomic and
metabolomic studies are needed for further analysis and
investigation.
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Contributing to Liver Disease
We would like to highlight and present a few examples of
other ways the microbiota contributes to liver disease. Both
NAFLD and NASH are strongly linked to obesity, type 2
diabetes mellitus, and the metabolic syndrome.100 A west-
ern diet rich in fats and carbohydrates contributes to
qualitative microbiota changes.101 The microbiota may
contribute to obesity and NAFLD in a number of ways, some
of which are quite unexpected. Alterations in the intestinal
microbiota increase energy extraction and fermentation of
dietary ﬁbers into oligosaccharides, monosaccharides, and
short-chain fatty acids, respectively.102 For instance, germ-
free mice are protected from HFD-induced weight gain
and obesity.103 There may be complex mechanisms
responsible for increased energy harvest from the diet by
bacteria.92 Transplantation of fecal microbiota from adult
female twin pairs discordant for obesity into germ-free mice
fed low-fat mouse chow, as well as diets representing
different levels of saturated fat and fruit and vegetable
consumption typical of the U.S. diet, increased total body
and fat mass as well as obesity-associated metabolic phe-
notypes.104 Moreover, despite gaining the same body weight
after HFD feeding, one group of mice developed hypergly-
cemia and had a high plasma concentration of proin-
ﬂammatory cytokines (called the “responders”), while the
second cohort remained normoglycemic and had lower
levels of systemic inﬂammation (“nonresponders”). Germ-
free mice colonized with intestinal microbiota from the
nonresponder group maintained normoglycemia whereas
germ-free mice transplanted with responder microbiota
showed hyperglycemia, hepatic macrovesicular steatosis,
more hepatic triglycerides, and an increased expression of
genes involved in de novo lipogenesis after HFD feeding.
Both groups developed comparable obesity. These results
suggest that gut microbiota contributes to the development
of NAFLD independently of obesity.105Figure 1. (See previous page). Host–microbiome interactions
genetics factors (NLRP3/6 deﬁciency via IL-18), and the muco
biome.3,45,46 Dysbiosis is often characterized by loss of beneﬁci
of the microbiota to synthesize saturated LCFA, which also cont
metabolize various nutrients, and their fermented products are a
bacterial metabolic activity including SCFA from otherwise no
acetaldehyde affect immune responses and epithelial integrity (
to tight junction disruption are inﬂammatory cytokines secreted
products such as LPS translocate through the intercellular spac
via transcytosis.83 These products and bacteria reach the liver vi
act as a ligand of pattern recognition receptors such as TLRs
Dietary choline is metabolized by the commensal bacteria to T
in NAFLD and progression to NASH.113–115 Gene expression of
microbiota increasing levels of free fatty acids in plasma via inhib
to dysbiosis and facilitate bacteria translocation.58 In addition
coordinates homeostatic IgA-directed targeting against comm
matory disease.52 As yet unidentiﬁed products or metabolites fr
alcoholic liver disease; AMP, antimicrobial peptides and proteins
fasting-induced adipocyte factor; IL interleukin; LCFA, long-ch
coholic fatty liver disease/steatohepatitis; NLRP, nucleotide-bind
short-chain fatty acid; TMA, trimethylamine; VLDL, very-low-deBacterial metabolites promote obesity and in particular
NAFLD. For instance, microbiota produce endogenous
ethanol through the fermentation of carbohydrates, a
physiologic pathway that is strongly enhanced in the pres-
ence of gut dysmotility (eg, associated with obesity, dia-
betes, or chronic alcohol abuse) or an excess of
carbohydrates in the diet.106,107 Obese animals have higher
blood ethanol levels.107 Once ethanol reaches the liver via
the portal vein, it can promote steatosis,108 oxidative stress,
and liver inﬂammation.15 Pediatric patients with NASH have
higher blood ethanol concentrations than healthy in-
dividuals or pediatric patients with NAFLD, suggesting that
endogenous ethanol production by the microbiota might be
important in the progression from simple hepatic steatosis
to NASH.15 Future metatranscriptomic and metabolomic
studies are required to conﬁrm these ﬁndings.
Ethanol canbemetabolized into acetaldehydebymicrobial
fermentation109 or by the host either in the liver or the in-
testine.110,111 Ethanol can reach the microbiome and intesti-
nal epithelia cells from either the luminal side or via diffusion
from the systemic blood circulation. Ethanol and in particular
its metabolic derivative acetaldehyde can disrupt intestinal
tight junctions and increase intestinal permeability.112
Conventionalization of adult germ-free C57BL/6 mice
with a normal microbiota harvested from the distal intestine
(cecum) of conventionally raised animals produces a
60% increase in body fat content and insulin resistance.
Fasting-induced adipocyte factor (Fiaf), a member of the
angiopoietin-like family of proteins, is selectively suppressed
in the intestinal epithelium of normal mice by conventional-
ization. Analysis of germ-free and conventionalized, wild-
type, and Fiaf-deﬁcient mice established that Fiaf is a
circulating lipoprotein lipase inhibitor and that its suppres-
sion is essential for the microbiota-induced deposition of
triglycerides in adipocytes.19
A dysbiotic microbiome associated with HFD metabo-
lizes and converts dietary choline into methylamines. Lower
hepatic choline levels reduce secretion of very-low-densityduring liver disease. Environmental factors (including diet),
sal immune system inﬂuence the composition of gut micro-
al intestinal bacteria. Ethanol directly suppresses the capacity
ributes to dysbiosis.25 A dysbiotic microbiota has the ability to
vailable to the host, inﬂuencing liver disease. The products of
ndigestible dietary ﬁbers, EtOH and its fermented product
disruption of tight junctions).106,112 Other factors contributing
from activated immune cells in the lamina propria.16 Microbial
e to the systemic circulation.67 Bacteria can also translocate
a the portal vein, where they are further metabolized or directly
promoting liver diseases as NAFLD, NASH, and ALD.67,85–88
MA. Hepatic choline deﬁciency lowers VLDL efﬂux resulting
Fiaf in intestinal epithelial cells can be inhibited by intestinal
ition of LPL.19 Suppression of AMP secretion might contribute
, loss of innate (MyD88-dependent) signaling in T cells that
ensal microbes results in dysbiosis and more severe inﬂam-
om the microbiota might exert hepatoprotective effects. ALD,
; DC, dendritic cells; EtOH, ethanol; FFA, free fatty acids; Fiaf,
ain fatty acids; LPL, lipoprotein lipase; NAFLD/NASH, nonal-
ing domain and leucine rich repeat-containing protein; SCFA,
nsity lipoprotein.
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ciency is linked to NAFLD and NASH115 and is a common
model of experimental NASH in rodents. Healthy subjects
develop a fatty liver on a choline-deﬁcient diet only if there
is a single-nucleotide polymorphism in the promoter region
of phosphatidylethanolamine N-methyltransferase, which
affects de novo synthesis of phosphatidylcholine.116 This is
an excellent example how environmental and genetic factors
synergize to cause liver disease. Causes for changes in the
intestinal microbiota composition and consequences of in-
testinal dysbiosis that are relevant for the pathogenesis of
chronic liver diseases are illustrated and summarized in
Figure 1.
Conclusion and Future Directions
The gut microbiome is composed of trillions of microbes
that inhabit the human intestine. This complex community
inﬂuences both normal physiology and disease susceptibil-
ities through its collective metabolic activities and host in-
teractions. We are just starting to understand the
mechanisms that result in dysbiosis and its functional con-
sequences for liver diseases. We need to further dissect the
mechanisms of how dysbiosis affects intestinal homeostasis
and causes the progression of liver disease beyond triggering
an increase in intestinal permeability. Genetic factors (single-
nucleotide polymorphisms, gene copy numbers, etc.) are
involved in shaping the composition of the gutmicrobiota and
modulating disease susceptibility or resistance.40,43,117 Given
that germ-free mice are more susceptible to experimental
liver ﬁbrosis, there might be hepatoprotective microbial
metabolites. Our ultimate goal should be to design therapies
that restore intestinal eubiosis and homeostasis. This could
be achieved by either targeting themicrobiota or the intestine
of the host. This goal is formidable because of the immense
diversity among themicrobiota, interpersonal variations, and
temporal ﬂuctuations in composition, which are especially
apparent in disease.References
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